Prf Technologies Ltd. · NASDAQ:PRFX
Prf Technologies — PainReform — Investor Presentation (January 2021)
16 slides from Prf Technologies's investor presentation, Jan 5, 2021
Slide 1: Investor Presentation January 2021
Investor Presentation January 2021
Slide 2: Forward-Looking Statements
2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be identified by the use of forward - looking words such as “be
Slide 3: Executive Summary
3 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Executive Summary ▪ Post - operative pain treatment is a growing market (~$12B) with a need for better therapeutics 1 o Local anesthetics provide pain relief for up to 6 hours and require augmentation with NSAIDs or opio
Slide 4: Management Team
4 PainReform Ltd. | www.painreform.com Post Operative Pain Management Management Team Sigal Aviel , PhD, MBA. Chief Operating Officer ▪ Over 20 years of managerial experience in the Biotech industry. ▪ Former Chief R&D Officer at MediWound , a company specializing in deep burns and chronic wound car
Slide 5: Post-Operative Pain Management Market Overview
5 PainReform Ltd. | www.painreform.com Post Operative Pain Management Post - Operative Pain Management Market Overview ▪ The 2017 world - wide overall post - operative pain treatment market was estimated at US$ 12 B and is expected to reach in excess of US$ 45 B by the end of 2026 1 ▪ Significant un
Slide 6: Problem: State of Opioid Crisis in America
6 PainReform Ltd. | www.painreform.com Post Operative Pain Management Problem: State of Opioid Crisis in America 1 NSDUH, 2017 Data; published Sept. 2018 2 Med Care 2016 54 ( 10 ) 901 - 906 , Article 3 Hollmann: Optimal postoperative pain management – redefining the role for opioids Study 4 NIH Horn
Slide 7: Current Approaches in Post-Operative Analgesia Are Lacking
7 PainReform Ltd. | www.painreform.com Post Operative Pain Management Current Approaches in Post - Operative Analgesia Are Lacking ▪ Poor efficacy in acute pain control ▪ Not intended for the treatment of post - operative pain Short - Acting Opioids ▪ Repeated dosing required ▪ Inconsistent pain con
Slide 8: PainReform Solution: PRF-110 Post Operative Pain Management
8 PainReform Ltd. | www.painreform.com Post Operative Pain Management PainReform Solution: PRF - 110 Post Operative Pain Management ▪ PainReform has developed a platform formulation for extended release of drugs ▪ Low COGS compared to current drug landscape ▪ Reliable PK and low Cmax ▪ No free API ▪
Slide 9: Timeline to NDA
9 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 : Timeline to NDA FDA agreed to PRF - 110 product designation of 505(b)(2) accelerated regulatory pathway for NDA approval FDA determined the CMC data adequate to proceed to Phase I study Phase I study demonstrated PRF -
Slide 10: PRF-110 Advantages versus Exparel and HTX-011
10 PainReform Ltd. | www.painreform.com Post Operative Pain Management Pacira 1 РExparel ΠHeron 2 - HTX 011 PRF - 110 PRF - 110 Advantages Formulation Watery, complex liposomal suspension Biochronomer technology (4) : Non - dilutable (Limited market) Waterless, viscous, oil - based solution (GRAS)
Slide 11: Safety
11 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Safety ▪ PainReform carried out extensive FDA requested wound healing and related animal studies that showed: x PRF - 110 allows for normal wound healing of surgical incisions equal to both Naropin ® and saline without
Slide 12: Phase 2 Results in Hernia
12 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 Phase 2 Results in Hernia ▪ Efficacy » PRF - 110 provided post - operative pain control for up to 72 hours after a single application ▪ Safety » PRF - 110 was well tolerated ▪ Ease of use » Easy to use and compliant wit
Slide 13: Phase III Clinical Trial Protocol
13 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 : Phase III Clinical Trial Protocol ▪ Two, double blind, placebo control 72 - hour treatment period , studies planned (bunionectomy and hernia repair). For each study: ▪ Three cohorts (n= ~400): 1. PRF - 110; 2. Naropin
Slide 14: Potential Best-In-Class
14 PainReform Ltd. | www.painreform.com Post Operative Pain Management PRF - 110 : Potential Best - In - Class Administration PRF - 110 viscosity and uniformity are highly suitable for standard surgical site administration. Efficacy Cross study comparison of Phase II data, 72 hours pain AUC Safety M
Slide 15: Summary
15 PainReform Ltd. | www.painreform.com Post Operative Pain Management Summary Large Unmet Need in Non - Opioid Postoperative Pain Management 1 1 Market Watch Post - Operative Pain Management Market Size Analysis 2019 Report Innovative Formulation / Delivery System Opioid Epidemic Presents Significa
Slide 16: PainReform
PainReform